Vanguard Group
TARA icon

Vanguard Group’s Protara Therapeutics TARA Stock Holding History

Vanguard Group’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$12.7M Buy
2,391,903
+487,747
+26% +$2.71M ﹤0.01% 2844
2025
Q3 		$8.28M Buy
1,904,156
+102,176
+6% +$331K ﹤0.01% 3070
2025
Q2 		$5.46M Buy
1,801,980
+199,128
+12% +$687K ﹤0.01% 3184
2025
Q1 		$6.83M Buy
1,602,852
+243,343
+18% +$1.09M ﹤0.01% 3051
2024
Q4 		$7.18M Buy
1,359,509
+599,897
+79% +$1.94M ﹤0.01% 3119
2024
Q3 		$1.39M Buy
759,612
+332,000
+78% +$682K ﹤0.01% 3669
2024
Q2 		$889K Hold
427,612
– – ﹤0.01% 3825
2024
Q1 		$1.71M Hold
427,612
– – ﹤0.01% 3640
2023
Q4 		$802K Hold
427,612
– – ﹤0.01% 3897
2023
Q3 		$714K Hold
427,612
– – ﹤0.01% 3946
2023
Q2 		$1.02M Hold
427,612
– – ﹤0.01% 3894
2023
Q1 		$1.34M Hold
427,612
– – ﹤0.01% 3820
2022
Q4 		$1.15M Buy
427,612
+224
+0.1% +$707 ﹤0.01% 3860
2022
Q3 		$1.26M Sell
427,388
-16
-0% -$54 ﹤0.01% 3927
2022
Q2 		$1.25M Hold
427,404
– – ﹤0.01% 4011
2022
Q1 		$2.18M Sell
427,404
-7,847
-2% -$41.3K ﹤0.01% 3919
2021
Q4 		$2.94M Sell
435,251
-562
-0.1% -$3.88K ﹤0.01% 3880
2021
Q3 		$3.02M Sell
435,813
-1,295
-0.3% -$10.1K ﹤0.01% 3911
2021
Q2 		$4.26M Sell
437,108
-19,425
-4% -$220K ﹤0.01% 3676
2021
Q1 		$7.19M Buy
456,533
+294,634
+182% +$5.46M ﹤0.01% 3341
2020
Q4 		$3.92M Buy
161,899
+142,373
+729% +$3.07M ﹤0.01% 3462
2020
Q3 		$329K Buy
19,526
+2,103
+12% +$48.8K ﹤0.01% 3884
2020
Q2 		$510K Buy
17,423
+8,211
+89% +$254K ﹤0.01% 3762
2020
Q1 		$212K Buy
9,212
+7,007
+318% +$204K ﹤0.01% 3855
2019
Q4 		$36K Hold
2,205
– – ﹤0.01% 4063
2019
Q3 		$23K Hold
2,205
– – ﹤0.01% 4126
2019
Q2 		$37K Sell
2,205
-3,644
-62% -$64.4K ﹤0.01% 4130
2019
Q1 		$118K Buy
5,849
+395
+7% +$45.1K ﹤0.01% 3998
2018
Q4 		$495K Buy
5,454
+219
+4% +$15.5K ﹤0.01% 3734
2018
Q3 		$408K Buy
5,235
+1,646
+46% +$152K ﹤0.01% 3885
2018
Q2 		$352K Sell
3,589
-1,613
-31% -$150K ﹤0.01% 3890
2018
Q1 		$520K Sell
5,202
-57
-1% -$5.18K ﹤0.01% 3778
2017
Q4 		$399K Buy
5,259
+48
+0.9% +$3.85K ﹤0.01% 3796
2017
Q3 		$417K Buy
5,211
+223
+4% +$12.8K ﹤0.01% 3785
2017
Q2 		$310K Sell
4,988
-960
-16% -$53.8K ﹤0.01% 3819
2017
Q1 		$416K Buy
5,948
+1,164
+24% +$87K ﹤0.01% 3783
2016
Q4 		$363K Buy
4,784
+1,108
+30% +$350K ﹤0.01% 3793
2016
Q3 		$1.37M Buy
3,676
+320
+10% +$113K ﹤0.01% 3497
2016
Q2 		$1.08M Sell
3,356
-373
-10% -$112K ﹤0.01% 3587
2016
Q1 		$1.15M Buy
3,729
+14
+0.4% +$4.51K ﹤0.01% 3558
2015
Q4 		$2.31M Buy
3,715
+65
+2% +$38.1K ﹤0.01% 3339
2015
Q3 		$2.03M Sell
3,650
-723
-17% -$448K ﹤0.01% 3370
2015
Q2 		$3.13M Sell
4,373
-752
-15% -$465K ﹤0.01% 3221
2015
Q1 		$2.38M Buy
5,125
+382
+8% +$168K ﹤0.01% 3327
2014
Q4 		$1.97M Buy
+4,743
New +$1.91M ﹤0.01% 3291

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group's TARA Position: Q4 2025 in Review

Vanguard Group increased its Protara Therapeutics (TARA) stake by 26% in Q4 2025, buying an estimated $2.71M and bringing the position to 2,391,903 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2844.

Vanguard Group first reported a position in TARA in Q4 2014 and has held it in 45 quarters since. 105 funds tracked by Wall St. Rank hold TARA as of Q4 2025.

  • Vanguard Group held 2,391,903 shares of Protara Therapeutics worth $12.7M as of Q4 2025.
  • Vanguard Group bought 487,747 Protara Therapeutics shares in Q4 2025, an estimated $2.71M.
  • Protara Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2844 holding.
  • Vanguard Group first reported a position in Protara Therapeutics in Q4 2014 and has held it in 45 quarters since.
  • 105 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.